Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | MAOA | P21397 | 6/20 | 0.59 |
| ▸ | MAOB | P27338 | 6/20 | 0.59 |
| ▸ | PRF1 | P14222 | 4/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | METAP1 | P53582 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29470781 | 0.84 | MAOA (0.62) | MAPTLMNAGAAMAOAMAOB | |
| SCHEMBL854490 | 0.84 | MAOA (0.62) | MAPTLMNAGAAMAOAMAOB | |
| SCHEMBL28425280 | 0.81 | SRD5A1 (0.45) | MAPTLMNAGAAMAOAMAOB | |
| SCHEMBL4170867 | 0.80 | MAPT (0.61) | MAPTLMNAGAAMAOAMAOB | |
| SCHEMBL30372059 | 0.80 | MAPT (0.61) | MAPTLMNAGAAMAOAMAOB | |
| SCHEMBL13870462 | 0.78 | MAPK14 (0.60) | MAPTGAAMAOAMAOBALDH1A1 | |
| SCHEMBL13151923 | 0.76 | HTR2B (0.39) | MAPTLMNAGAAMAOAMAOB | |
| SCHEMBL365201 | 0.76 | MAPT (0.61) | MAPTLMNAGAAMAOAMAOB | |
| SCHEMBL87174 | 0.76 | MAPT (0.61) | MAPTLMNAGAAMAOAMAOB | |
| SCHEMBL256733 | 0.76 | MAPT (0.61) | MAPTLMNAGAAMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4570901-A1 | METHOD FOR SELECTIVE REMOVAL OF UNDIFFERENTIATED PLURIPOTENT STEM CELLS | Buddhist Tzu Chi Medical Foundation (TW) | 2025-06-18 | — | — | EP | claimed |
| US-20250188411-A1 | METHOD FOR SELECTIVE REMOVAL OF UNDIFFERENTIATED PLURIPOTENT STEM CELLS | BUDDHIST TZU CHI MEDICAL FOUNDATION (TW) | 2025-06-12 | — | — | US | claimed |
| CN-116239635-A | 2-amino-8-hydroxyquinoline nickel complex for resisting drug-resistant ovarian cancer and preparation method thereof | 玉林师范学院 | 2023-06-09 | — | — | CN | claimed |
| US-7271273-B2 | Method for the preparation of citalopram | H. LUNDBECK A/S (DK) | 2007-09-18 | — | — | US | claimed |
| US-20060079700-A1 | Method for the preparation of citalopram | H. LUNDBECK A/S (DE) | 2006-04-13 | — | — | US | claimed |
| EP-1246813-B1 | METHOD FOR THE PREPARATION OF CITALOPRAM | LUNDBECK & CO AS H (DK) | 2003-11-05 | — | — | EP | claimed |
| JP-2003519218-A | — | — | 2003-06-17 | — | — | JP | claimed |
| US-20020198391-A1 | METHOD FOR THE PREPARATION OF CITALOPRAM | H. LUNDBECK A/S (DK) | 2002-12-26 | — | — | US | claimed |
| EP-1246813-A1 | METHOD FOR THE PREPARATION OF CITALOPRAM | H. Lundbeck A/S (DK) | 2002-10-09 | — | — | EP | claimed |
| WO-2001049672-A1 | METHOD FOR THE PREPARATION OF CITALOPRAM | H. LUNDBECK A/S (DK) | 2001-07-12 | — | — | WO | claimed |
| US-20250289830-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2025-09-18 | — | — | US | disclosed |
| US-12351591-B2 | KRas inhibitors | ELI LILLY AND COMPANY (US) | 2025-07-08 | — | — | US | disclosed |
| EP-4570901-A1 | METHOD FOR SELECTIVE REMOVAL OF UNDIFFERENTIATED PLURIPOTENT STEM CELLS | Buddhist Tzu Chi Medical Foundation (TW) | 2025-06-18 | — | — | EP | disclosed |
| CN-120137900-A | Method for selectively removing undifferentiated pluripotent stem cells | 佛教慈济医疗财团法人 | 2025-06-13 | — | — | CN | disclosed |
| US-20250188411-A1 | METHOD FOR SELECTIVE REMOVAL OF UNDIFFERENTIATED PLURIPOTENT STEM CELLS | BUDDHIST TZU CHI MEDICAL FOUNDATION (TW) | 2025-06-12 | — | — | US | disclosed |
| EP-0911320-B1 | 1,2-Di-substituted benzenecarboxamide derivative, hair growth promoter and external composition for skin using the same | SHISEIDO CO LTD (JP) | 2002-07-24 | — | — | EP | disclosed |
| WO-2002050067-A2 | PHARMACEUTICAL HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 2002-06-27 | — | — | WO | disclosed |
| WO-2001049672-A1 | METHOD FOR THE PREPARATION OF CITALOPRAM | H. LUNDBECK A/S (DK) | 2001-07-12 | — | — | WO | disclosed |
| US-6114325-A | 1,2-di-substituted benzene-carboxamide derivative, hair growth promoter and external composition for skin using the same | SHISEIDO CO., LTD. (JP) | 2000-09-05 | — | — | US | disclosed |
| EP-0911320-A2 | 1,2-Di-substituted benzenecarboxamide derivative, hair growth promoter and external composition for skin using the same | SHISEIDO COMPANY LIMITED (JP) | 1999-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079700-A1 | Method for the preparation of citalopram | HTR5A, HTR3C, HTR3B | MAPT 255/4885LMNA 698/4885GAA 1672/4885 |
| US-20020198391-A1 | METHOD FOR THE PREPARATION OF CITALOPRAM | HTR5A, HTR3C, HTR3B | MAPT 255/4885LMNA 698/4885GAA 1672/4885 |
| US-12351591-B2 | KRas inhibitors | KRAS, NRAS, HRAS | MAPT 4564/4885LMNA 3550/4885GAA 1287/4885 |
| US-20250289830-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | MAPT 4564/4885LMNA 3550/4885GAA 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.